Jan 28, 2020
18-MC is a manmade derivative of the hallucinogen ibogaine but doesn't have the hallucinogenic effects, yet still contains the other benefits for addiction therapy. Ibogaine has long been used for opioid withdrawal and as an addition interrupter for opioid addiction, meth addiction, nicotine addiction, and more. MindMed, a Silicon Valley startup company, purchased 18-MC and the team behind it to start human trials with the ultimate goal of getting FDA approval to market the new 'Wonder Drug'.